Comparative Efficacy and Safety of Upadacitinib vs. Tocilizumab in Methotrexate-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500104153

Enrollment

Unknown

Registered

2025-06-11

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Group A (UPA+MTX):None

Group B (TCZ+MTX):None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 Meet the 2010 ACR/EULAR classification criteria for RA, 2 Age >=18 years, 3 Moderate to severe active RA defined as DAS28 score >3.2, 4 Inadequate response to methotrexate (MTX) after >=3 months of treatment, 5 Complete clinical case data available, 6 Patients voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1 Current active tuberculosis or hepatitis infection, severe infections, or malignancy, 2 Other autoimmune diseases (excluding those secondary to RA), 3 New thromboembolic events within the past three months or with multiple organ dysfunction, 4 Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
ACR20;	—

Secondary

Measure	Time frame
ACR50;ACR70;	—

Countries

China

Contacts

Public ContactZhang Yan

The Second Hospital of Dalian Medical University

zhangy1971@163.com+86 177 0987 3636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026